Affordable access to insulin is life-saving and sustaining for more than 1.1 million Illinoisans who live with diabetes.
January 24, 2020
Affordable access to insulin is life-saving and sustaining for more than 1.1 million Illinoisans who live with diabetes.
During the recent veto session in Springfield, the Shriver Center advocated for Senate Bill 667, which would impose a $100 cap on copayments for insulin, and require further study of prescription drug costs by the state Department of Insurance.
This important bill passed overwhelmingly with bi-partisan support in both chambers of the Illinois General Assembly and was signed into law by Governor Pritzker on January 24, 2020.
“The passage of SB 667 is a victory for those who have faced extraordinary price increases for this life-saving medicine. This is not only an economic issue for people with diabetes, but it’s also a health equity issue: people of color with diabetes are more likely to underuse their medication in order to prolong supply due to cost, resulting in poor health outcomes. We know there is much more work to be done to make prescription medication more affordable for everyone, but this is a step in the right direction for consumers,” said Stephani Becker, Associate Director of Healthcare Justice at the Shriver Center.
We are intentional about addressing barriers to healthcare that specific communities experience.
Healthcare is a human right. The high cost of care means millions of families have no access to the critical care all human beings deserve.